Biochemistry

Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives

Retrieved on: 
Thursday, January 25, 2024
Professional Services, Health, Other Health, Other Science, Finance, Science, Biotechnology, Constellation, Bristol Myers Squibb, Vyasa, Philosophy, Biochemistry, Celgene, Patient, Outline of health sciences, Courtney, Therapy, Thought, Flare, Biology, Partnership, Rutgers University, Third Rock Ventures, GSK, University, Biogen, Harvard University, Tulane University, Economics, MBA, AB, Acquisition, Harvard Business School, Harvard College, IPO, Rock Ventures, Purdue University, Psychology, Ewing Marion Kauffman Foundation, Columbia University, Doctor of Philosophy, Jigar, Kearney (consulting firm), Beam Therapeutics

Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.

Key Points: 
  • Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
  • Jigar, who joined Third Rock in 2021 as a venture partner, has made significant contributions to the firm’s discovery and company creation activities.
  • Steve Paul, M.D., who has been affiliated with Third Rock since 2010, has re-joined as a venture partner.
  • Prior to Third Rock, Courtney was an early employee and the chief business officer of Beam Therapeutics.

Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors

Retrieved on: 
Thursday, January 25, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Transfer, Spark Therapeutics, Biochemistry, Therapy, Biology, Molecular biology, University, Immunology, Medical research, Doctor of Philosophy, Drexel University, Huber loss, Pharmaceutical industry

Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.

Key Points: 
  • Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.
  • Federico brings over 25 years of experience in gene therapy, immunology, as well as biochemistry and molecular biology in academia and industry.
  • Federico has participated in numerous clinical trials targeting metabolic and neuromuscular diseases, hereditary blindness, and coagulation disorders.
  • Khalil Barrage, ad interim Chair of Sensorion's Board of Directors, said: "We are delighted to welcome Federico Mingozzi as new director.

Former Administrative Patent Judge and Associate Solicitor Kristi L.R. Sawert, Ph.D., Joins Fish & Richardson, Expanding Post-Grant Practice and Life Science Focus

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Other Science, Other Technology, Medical Devices, Research, Legal, Science, Intellectual property, Biochemistry, House, Professional, Internet, Biology, Heart, Associate, Patent, Justice, Policy, Multimedia, Chemistry, Knowledge, The Honourable, Berea College, Government, Computer, Inter partes, PTE, Supreme court, PTAB, Doctor of Philosophy, Ohio State University, Fish & Richardson, Pharmaceutical industry

Today former U.S. Patent Trial and Appeal Board Administrative Patent Judge and Associate Solicitor Kristi L.R.

Key Points: 
  • Today former U.S. Patent Trial and Appeal Board Administrative Patent Judge and Associate Solicitor Kristi L.R.
  • As a principal, Dr. Sawert will focus her experience on representing life sciences clients, particularly in biotechnology and pharmaceuticals.
  • “Kristi brings a rare and valuable combination of law firm and government experience to Fish,” said John Adkisson, Fish president & chief executive officer.
  • “During my tenure as an administrative patent judge, I had the opportunity to see firsthand the impressive professionalism, preparedness, and skill of Fish attorneys,” said Sawert.

NexCore Group Opens New HATCHspaces® Life Science Building in Boulder, Colorado

Retrieved on: 
Wednesday, January 24, 2024
Student, MEP, Wilderness, Research, Computer science and engineering, Partnership, Science, CBA, University, SF, Boulder Beer Company, Workflow, Biochemistry, Ecosystem, Non-Euclidean geometry, Laboratory, Incubator, Artifact, University of Colorado Boulder, Management

Denver, Jan. 24, 2024 /PRNewswire-PRWeb/ -- NexCore Group and its subsidiary, HATCHspaces, have marked the inauguration of HATCHlabs @ Wilderness Place in Boulder, Colorado, on January 17, 2024. Situated at 2880 Wilderness Place and representing the successful conversion of the historic Boulder Beer Company Brewery building into an innovative hub for emerging companies in the life sciences industry. This project marks the ninth project overall for the HATCHspaces brand and the fourth under the NexCore Science & Technology platform.

Key Points: 
  • This project marks the ninth project overall for the HATCHspaces brand and the fourth under the NexCore Science & Technology platform .
  • In order for life science clusters to grow, functional and affordable graduation lab space needs to be available for startups emerging from academic labs and incubators.
  • "In order for life science clusters to grow, functional and affordable graduation lab space needs to be available for startups emerging from academic labs and incubators.
  • "Huge kudos to HATCHspaces and NexCore Group for selecting Colorado as a key market.

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Retrieved on: 
Wednesday, January 24, 2024
Entrepreneurship, Student, Neuroscience, Regeneron Pharmaceuticals, Biochemistry, Materials science, Physics, Research, Environmental science, Mathematics, Animal, Nobel Prize, Social, Knowledge, Chemistry, School, Society, Molecular biology, Medicine, Anxiety, Botany, DSM-IV codes, Creativity, College of Engineering (KNUST), Computational biology, Society for Science, Science News

TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)
    TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search , the nation's oldest and most prestigious science and math competition for high school seniors.
  • "We applaud this dynamic group of Regeneron Science Talent Search finalists on their impressive achievement," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The top 10 Regeneron Science Talent Search 2024 winners will be announced during an awards ceremony on March 12, streamed live from Washington D.C.
  • In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search.

Dr. Jon Ver Halen Scholarship for Future Doctors Unveils Opportunity for Medical Students

Retrieved on: 
Tuesday, January 16, 2024
Student, Biochemistry, Vanderbilt University, Texas A&M University, Harvard Medical School, University, Medicine, Worldwide Angel, Patient, Dentistry, MD Anderson Cancer Center, UCLA, Hospital, Letter, Physician, Nursing

DALLAS, Jan. 16, 2024 /PRNewswire/ -- In a significant stride towards fostering the next generation of medical professionals, the esteemed Dr. Jon Ver Halen announces the establishment of the Dr. Jon Ver Halen Scholarship for Future Doctors.

Key Points: 
  • DALLAS, Jan. 16, 2024 /PRNewswire/ -- In a significant stride towards fostering the next generation of medical professionals, the esteemed Dr. Jon Ver Halen announces the establishment of the Dr. Jon Ver Halen Scholarship for Future Doctors.
  • Dr. Jon Ver Halen , a distinguished plastic surgeon based in Dallas, Texas, founded this scholarship as a testament to his commitment to supporting aspiring medical professionals.
  • Internationally recognized for his surgical expertise and research achievements, Dr. Jon Ver Halen has contributed over 40 peer-reviewed articles to the medical community.
  • Applications for the Dr. Jon Ver Halen Scholarship for Future Doctors must be submitted by August 15, 2024.

TruSteel Announces Acquisition By Original Founder, Ray Van Lenten

Retrieved on: 
Wednesday, January 10, 2024
DNA, Food, Biochemistry, Acquisition, Research, Retail

The recent acquisition of a controlling stake by Ray Van Lenten, TruSteel's Chief Technology Officer, signifies a renewed vision for the company.

Key Points: 
  • The recent acquisition of a controlling stake by Ray Van Lenten, TruSteel's Chief Technology Officer, signifies a renewed vision for the company.
  • "This marks a natural progression for TruSteel," Van Lenten stated.
  • Van Lenten emphasized, "Our goal is to redefine industry standards, empowering customers with sustainable solutions that address evolving needs."
  • The acquisition solidifies Ray Van Lenten's role as majority stakeholder and CTO, securing TruSteel's position as an industry leader and innovator.

Dr. Adam Perlman, Former Medical Director at Mayo Clinic, Joins Pendulum Therapeutics as Chief Medical Officer

Retrieved on: 
Tuesday, January 9, 2024
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Alternative medicine, Biochemistry, Stanford University, Patient, Overalls, Research, Associate, Internal medicine, Multimedia, Johns Hopkins University, Science, Wellness, Sequoia Capital, Meritech Capital Partners, Medicine, Duke University Health System, Prediabetes, Mayo Clinic, FACP, Clinical professor, Duke University, PGC, IND, Cornell University, Conditional sentence, FDA, Doctor of Philosophy, Khosla Ventures, MPH, Clinical trial, Microbiology, Medical device

- Today, Pendulum Therapeutics , the leading microbiome biotech company pioneering the next frontier of metabolic health, announced that former Mayo Clinic Medical Director and Executive Director for Integrative Medicine at Duke University, Adam Perlman, MD, MPH, FACP, has joined the company as Chief Medical Officer.

Key Points: 
  • - Today, Pendulum Therapeutics , the leading microbiome biotech company pioneering the next frontier of metabolic health, announced that former Mayo Clinic Medical Director and Executive Director for Integrative Medicine at Duke University, Adam Perlman, MD, MPH, FACP, has joined the company as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240109713201/en/
    Dr. Perlman, Chief Medical Officer at Pendulum Therapeutics (Photo: Pendulum Therapeutics)
    As Chief Medical Officer at Pendulum, he will oversee the company’s clinical research portfolio, working internally and with academic collaborators to uncover new insights and inform the development of new products that will deliver strong clinical efficacy and outcomes for consumers.
  • Dr. Perlman saw first hand the efficacy of Pendulum probiotics in his practice, observing benefits in his patients with pre-diabetes and type 2 diabetes.
  • Berry joined Pendulum’s all-star lineup of investors, including Sequoia Capital, Meritech Capital, True Ventures, Khosla Ventures and the Mayo Clinic.

National Korea Maritime and Ocean University Researchers Explore the Impact of Microplastics and Toxin Exposure on Goldfish

Retrieved on: 
Thursday, January 11, 2024
Endocrine system, BAP, Toxicology, Health, DNA, Biochemistry, DNA repair, Plastic, Travel, Goldfish, Toxicity, Food chain, Pharmacology, Microplastics, Aquaculture

The presence of microplastics, ranging in size from 100 nanometers to 5 millimeters, is particularly concerning.

Key Points: 
  • The presence of microplastics, ranging in size from 100 nanometers to 5 millimeters, is particularly concerning.
  • Another aspect of microplastic pollution, often overlooked but equally dangerous, is their ability to absorb and carry harmful chemicals, such as persistent organic pollutants.
  • Understanding the extent of toxicity and threat posed by the combined impact of exposure to microplastics and other pollutants is, therefore, important.
  • In a recent study now, researchers led by Dr. Cheol Young Choi from National Korea Maritime and Ocean University explored the impact of microplastic and BaP exposure on freshwater goldfish (Carassius auratus), who were exposed to BaP and microplastics individually and in combination, to understand their exposure effects.

L.E.K. Consulting Announces 11 New Global Partner Promotions

Retrieved on: 
Tuesday, January 9, 2024
Master of Engineering, ChromeOS, Stanford University, Biochemistry, School, Wellesley College, Imperial College London, London Business School, Master of Research, Tuck School of Business, Emlyon Business School, Health care, Mathematics, Commerce, Bell, Tuchman, University, Business, Consumer, Hydrogen, Digital, Babson College, Global education, Environment, Dartmouth College, Recycling, MBA, Bachelor of Science, Medtech, King's College London, Doctor of Philosophy, Pharma, St. Stephen's College, Master of Science, Mechanical engineering, L.E.K. Consulting, Construction, Organization, College, Queen's University, Education, Nataraja, Timm, Management

Consulting has elected 11 new partners.

Key Points: 
  • Consulting has elected 11 new partners.
  • The promotions recognize the significant expertise and insights that these leaders bring to bear for clients across multiple industry sectors and geographies who are facing critical decisions.
  • "We are pleased to announce the newest partner appointments at L.E.K.
  • With gratitude and pride, we congratulate them on this accomplishment and look forward to their continued impact and contributions to both our clients and our firm," said Clay Heskett, Global Manager Partner at L.E.K.